Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04290663 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up

Study acronym: INTERMEDIATE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 476 to 368
    • Site contacts updated at 1 of 29 sites
    v11
  2. Study sites revised (29)v10
  3. Study sites: 28 to 29v9
  4. Site contacts updated at 1 of 28 sitesv8
  5. Site contacts updated at 1 of 28 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 27 to 28v6
  2. Primary completion date: Feb 2026 to Feb 2031v5 Show 4 more changesShow less
    • Study sites: 1 to 27
    • Study completion date: Feb 2028 to Feb 2033
    • Eligibility criteria revised
    • Study title shortened, about 5 words
  3. Re-verified, no change to tracked fieldsv4
  4. Eligibility criteria expanded, about 56 wordsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2020 to Mar 2, 2020
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy
Trial Details
NCT Number NCT04290663
Lead Sponsor Centre Francois Baclesse
Collaborators: French cancer Institute INCa
Conditions
(from sponsor)		 Thyroid Cancer, Intermediate Risk
Related terms Thyroid Neoplasms
Enrollment 368 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov